Showing results (31-40 of 50) with videos related to
Sort By:
Pageof 5
Multiple Sclerosis and Related Disorders|March 7, 2020
Socioeconomic status and disease-modifying therapy prescribing patterns in people with multiple sclerosisSaúl Reyes, Sebastian Suarez, Kimberley Allen-Philbey, et al.Multiple Sclerosis and Related Disorders|December 6, 2021
Factors contributing to CSF NfL reduction over time in those starting treatment for multiple sclerosis: An observational studyIde Smets, David Holden, Lucia Bianchi, et al.Plos One|August 13, 2013
Biomarker report from the phase II lamotrigine trial in secondary progressive MS - neurofilament as a surrogate of disease progressionSharmilee Gnanapavan, Donna Grant, Steve Morant, et al.Practical Neurology|July 8, 2020
Protecting people with multiple sclerosis through vaccinationSaúl Reyes, Mary Ramsay, Shamez Ladhani, et al.Journal of Immunology (Baltimore, Md. : 1950)|March 21, 2009
Advanced intercross line mapping suggests that ncf1 (ean6) regulates severity in an animal model of guillain-barre syndromeAlexander Huberle, Amennai Daniel Beyeen, Johan Ockinger, et al.Journal of the Neurological Sciences|August 12, 2020
Serum neurofilament-light concentration and real-world outcome in MSValerie Anderson, Emily Bentley, Sam Loveless, et al.Multiple Sclerosis and Related Disorders|July 11, 2018
A phase II baseline versus treatment study to determine the efficacy of raltegravir (Isentress) in preventing progression of relapsing remitting multiple sclerosis as determined by gadolinium-enhanced MRI: The INSPIRE studyJulian Gold, Monica Marta, Ute C Meier, et al.Neurobiology of Disease|August 24, 2014
Acute treatment with valproic acid and l-thyroxine ameliorates clinical signs of experimental autoimmune encephalomyelitis and prevents brain pathology in DA ratsGonçalo Castelo-Branco, Pernilla Stridh, André Ortlieb Guerreiro-Cacais, et al.Multiple Sclerosis Journal - Experimental, Translational and Clinical|August 10, 2018
Cladribine: Off-label disease modification for people with multiple sclerosis in resource-poor settings?Zhifeng Mao, César Álvarez-Gonzalez, Stefania De Trane, et al.Therapeutic Advances in Neurological Disorders|November 13, 2023
Disease activity 4.5 years after starting cladribine: experience in 264 patients with multiple sclerosisKimberley Allen-Philbey, Stefania De Trane, Amy MacDougall, et al.Pageof 5